Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
Carmen Bozic, M.D.

Carmen Bozic, M.D.

Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer

Carmen has deep experience leading global clinical development programs across all phases of development across all phases of development and across multiple diseases and therapeutic modalities. She joined Vertex in 2019 and is responsible for developing and driving the execution of our clinical development programs, including clinical development, medical affairs, drug safety, global clinical operations and biometrics. 

She graduated with her medical degree from McGill University, where she also completed a residency in internal medicine and served as Chief Resident. She completed a combined fellowship in pulmonary and critical care medicine at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center. 

Carmen serves as a member of the Clinical Advisory Committee at Akili Interactive. Previously she was the industry representative to the U.S. Food and Drug Administration’s Risk Communication Advisory Committee and was a member of PhRMA’s Clinical and Preclinical Development Committee. 

Carmen has deep experience leading global clinical development programs across all phases of development across all phases of development and across multiple diseases and therapeutic modalities. She joined Vertex in 2019 and is responsible for developing and driving the execution of our clinical development programs, including clinical development, medical affairs, drug safety, global clinical operations and biometrics. 

She graduated with her medical degree from McGill University, where she also completed a residency in internal medicine and served as Chief Resident. She completed a combined fellowship in pulmonary and critical care medicine at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center. 

Carmen serves as a member of the Clinical Advisory Committee at Akili Interactive. Previously she was the industry representative to the U.S. Food and Drug Administration’s Risk Communication Advisory Committee and was a member of PhRMA’s Clinical and Preclinical Development Committee.